Compare Kyndryl Holdings Inc (KD) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs Novo Nordisk A/S — how do they compare? Kyndryl Holdings Inc trades at $13.43 (market cap $2.91B), while Novo Nordisk A/S trades at $46.32 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 71.4× Kyndryl Holdings Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals.
| KD | NVO | |
|---|---|---|
Market Cap | $2.91B | $207.85B |
Sector | Technology | Health |
52-Week High | $33.14 | $63.98 |
52-Week Low | $10.59 | $35.29 |
Enterprise Value | $5.74B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kyndryl (KD) trades at $13.025, down 4.44% on the day, with a neutral technical signal. The company reported a net loss in Q1 2027, missing revenue estimates, but maintains a strong cash flow position with $942M from operations in 2025. Recent news highlights strategic acquisitions and AI service expansions, while an ongoing legal investigation introduces uncertainty. The stock's valuation shows a high P/E of 36.11 but attractive EV/EBITDA of 4.04, with analyst consensus leaning hold.
The outlook is mixed: positive cash flow and strategic moves in AI modernization offer growth potential, but recent earnings misses and legal scrutiny pose risks. Investors should weigh the company's turnaround progress against execution challenges and market sentiment.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
